• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Ipcalab Share Price

    Ipca Laboratories Share PriceIpca Laboratories

    Large Cap 7.5k Result
    ₹1,149.7
    16.75 (1.48%)
    • Advice
    • Hold
    As on 02 December, 2023 | 20:03 BSE: 524494 NSE: IPCALABISIN: INE571A01038
    Split

    Ipca Laboratories Performance

    Day Range

    • Low 1,123.95
    • High 1,153.00
    ₹ 1,149.7

    52 Week Range

    • Low 669.80
    • High 1,153.00
    ₹ 1,149.7
    • Open Price1,133.00
    • Previous Close1,132.95
    • Volume304454

    Start SIP in Ipca Laboratories

    Start SIP

    Ipca Laboratories Share Price

    • Over 1 Month 17.47%
    • Over 3 Month 32.64%
    • Over 6 Month 62.96%
    • Over 1 Year 32.97%

    Ipca Laboratories Key Statistics

    P/E Ratio 59.3
    PEG Ratio -3
    Market Cap Cr 29,168
    Price to Book Ratio 4.9
    EPS 19.2
    Dividend 0.2
    Relative Strength Index 75.15
    Money Flow Index 82.03
    MACD Signal 34.14
    Average True Range 27.25

    Ipca Laboratories F&O

    Ipca Laboratories Futures
    Ipca Laboratories Option Chain

    Ipca Laboratories Investment Rating

    • Master Rating:

    • Ipca Laboratories has an operating revenue of Rs. 6,679.17 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 12% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 35% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 64 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Ipca Laboratories Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,6631,4891,4021,4331,4851,4691,168
    Operating Expenses Qtr Cr 1,3541,1911,2261,2191,2131,212989
    Operating Profit Qtr Cr 309298176214272257179
    Depreciation Qtr Cr 61605957555352
    Interest Qtr Cr 39311810973
    Tax Qtr Cr 83834752777227
    Net Profit Qtr Cr 16216785120168144110
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 5,9265,455
    Operating Expenses Annual Cr 4,9034,156
    Operating Profit Annual in Cr 9121,244
    Depreciation Cr 229204
    Interest Annual Cr 447
    Tax Annual Cr 245217
    Net Profit Annual Cr 506871
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 840
    Cash from Investing Activity Annual Cr -824
    Cash from Financing Annual Activity Cr 426
    Net Cash Flow Annual Cr 442
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 5,8775,523
    Fixed Assets Annual Cr 2,6022,374
    Total Non Current Assets Annual Cr 3,5723,276
    Total Current Assets Annual Cr 4,8754,191
    Total Assets Annual Cr 8,4477,467
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 232218
    ROE Annual % 916
    ROCE Annual % 1218
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1824
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 2,0341,5881,5121,5461,6011,5861,289
    Operating Expenses Qtr Cr 1,7131,2801,3311,3301,3401,3171,070
    Operating Profit Qtr Cr 321308181216261269219
    Depreciation Qtr Cr 90697067646261
    Interest Qtr Cr 44311811973
    Tax Qtr Cr 88864854777429
    Net Profit Qtr Cr 14516377108144143130
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 6,3705,896
    Operating Expenses Annual Cr 5,3184,521
    Operating Profit Annual in Cr 9271,309
    Depreciation Cr 262232
    Interest Annual Cr 468
    Tax Annual Cr 253225
    Net Profit Annual Cr 471884
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 856
    Cash from Investing Activity Annual Cr -855
    Cash from Financing Annual Activity Cr 427
    Net Cash Flow Annual Cr 428
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 5,8425,492
    Fixed Assets Annual Cr 2,8542,670
    Total Non Current Assets Annual Cr 3,4373,182
    Total Current Assets Annual Cr 5,1894,457
    Total Assets Annual Cr 8,6267,639
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 233220
    ROE Annual % 816
    ROCE Annual % 1219
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1724
    Invest in Ipca Laboratories

    Ipca Laboratories Technicals

    EMA & SMA

    Current Price
    ₹1,149.7
    16.75 (1.48%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹1,070.05
    • 50 Day
    • ₹1,008.27
    • 100 Day
    • ₹946.66
    • 200 Day
    • ₹900.26
    • 20 Day
    • ₹1,064.74
    • 50 Day
    • ₹993.82
    • 100 Day
    • ₹928.54
    • 200 Day
    • ₹845.63

    Ipca Laboratories Resistance and Support

    PIVOT
    ₹1,142.22
    Resistance
    First Resistance 1,160.48
    Second Resistance 1,171.27
    Third Resistance 1,189.53
    RSI 75.15
    MFI 82.03
    MACD Single Line 34.14
    MACD 39.29
    Support
    First Resistance 1,131.43
    Second Resistance 1,113.17
    Third Resistance 1,102.38

    Ipca Laboratories Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 316,599 14,069,660 44.44
    Week 414,943 18,610,194 44.85
    1 Month 387,838 14,272,421 36.8
    6 Month 642,692 28,304,165 44.04

    Ipca Laboratories Result Highlights

    Ipca Laboratories Synopsis

    NSE-Medical-Generic Drugs

    Ipca Laboratorie is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 5814.62 Cr. and Equity Capital is Rs. 25.37 Cr. for the Year ended 31/03/2023. Ipca Laboratories Ltd. is a Public Limited Listed company incorporated on 19/10/1949 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1949PLC007837 and registration number is 007837.
    Market Cap 29,168
    Sales 5,986
    Shares in Float 13.70
    No of funds 223
    Yield 0.17
    Book Value 4.96
    U/D Vol ratio 2.3
    LTDebt / Equity 11
    Alpha 0.11
    Beta 0.39

    Ipca Laboratories

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 46.29%46.29%46.29%46.29%
    Mutual Funds 30.23%30.27%29.94%29.79%
    Insurance Companies 4.12%4.26%3.61%3.76%
    Foreign Portfolio Investors 9.86%10.05%10.58%10.46%
    Financial Institutions/ Banks 0.01%
    Individual Investors 7.14%6.98%7.26%7.41%
    Others 2.36%2.14%2.32%2.29%

    Ipca Laboratories Management

    Name Designation
    Mr. Premchand Godha Chairman & M.D & CEO
    Mr. Ajit Kumar Jain Joint Managing Director & CFO
    Mr. Pranay Godha Executive Director
    Mr. Prashant Godha Executive Director
    Mr. Anand T Kusre Independent Director
    Mr. Dev Parkash Yadava Independent Director
    Dr.(Mrs.) Manisha Premnath Independent Director
    Mr. Kamal Kishore Seth Independent Director

    Ipca Laboratories Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Ipca Laboratories Corporate Action

    Date Purpose Remarks
    2023-11-10 Quarterly Results & Interim Dividend
    2023-08-10 Quarterly Results
    2023-05-29 Audited Results
    2023-02-14 Quarterly Results
    2022-11-11 Quarterly Results & Interim Dividend
    Date Purpose Remarks
    2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
    2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
    2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
    Date Purpose Remarks
    2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

    Ipca Laboratories MF Shareholding

    Name Amount(cr)
    HDFC Balanced Advantage Fund Growth 63,981
    ICICI Prudential Balanced Advantage Fund Growth 49,871
    HDFC Mid-Cap Opportunities Fund Growth 47,846
    Parag Parikh Flexi Cap Regular Growth 44,038
    Kotak Emerging Equity Scheme Growth 33,700

    Ipca Laboratories FAQs

    What is Share Price of Ipca Laboratories ?

    Ipca Laboratories share price is ₹1,149 As on 02 December, 2023 | 19:49

    What is the Market Cap of Ipca Laboratories ?

    The Market Cap of Ipca Laboratories is ₹29168.4 Cr As on 02 December, 2023 | 19:49

    What is the P/E ratio of Ipca Laboratories ?

    The P/E ratio of Ipca Laboratories is 59.3 As on 02 December, 2023 | 19:49

    What is the PB ratio of Ipca Laboratories ?

    The PB ratio of Ipca Laboratories is 4.9 As on 02 December, 2023 | 19:49

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.